A Rat THC Binding Study Paired Partial Open-Field Tolerance With Regional Receptor-Density Changes

A 1994 rat study paired repeated-THC changes in open-field behavior with lower cannabinoid-receptor density in selected brain regions. Behavioral effects became smaller but did not all disappear, limiting an all-or-nothing account of tolerance.

The open-field measures were separate

Locomotion, exploration and time spent inactive changed differently after repeated exposure. Their attenuation should not be collapsed into complete behavioral recovery. A laboratory movement pattern also cannot independently establish a human's functional impairment.

The binding work had defined regional sampling

The researchers characterized binding in striatal, limbic-forebrain and ventral-mesencephalic preparations. The supplied abstract reported significant density decreases in the striatum and limbic forebrain. It does not establish an identical effect in every brain area or every receptor system.

The association was not a complete causal test

A molecular change accompanying tolerance can motivate an explanatory hypothesis. It does not prove that the measured density change alone produced each behavioral effect. The available abstract is truncated, so details absent from it should not be reconstructed as findings.

Interpreting the evidence

The useful conclusion is a paired behavioral and regional binding observation under one rat regimen. It does not validate receptor density as a personal tolerance measure or establish that a lower binding signal predicts absence of all THC effects.

Related reading: interpreting cannabis tolerance claims.

Research reference

Rodríguez de Fonseca F; Gorriti MA; Fernández-Ruiz JJ; Palomo T; Ramos JA (1994). Downregulation of rat brain cannabinoid binding sites after chronic delta 9-tetrahydrocannabinol treatment. Pharmacology, biochemistry, and behavior. doi:10.1016/0091-3057(94)90108-2.

This analysis draws on the supplied study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

A 2017 drug-discovery report described APD371, a selective CB2 agonist, maintaining its effect during a five-day rat osteoarthritis-pain protocol. That short preclinical finding is different from established long-term clinical efficacy. The report concerned selection of a development candidate The authors considered receptor efficacy, pharmacokinetics and pharmaceutical properties alongside an oral…

Spread the love

Read Article: APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

A 2021 rat study found sustained pain-response effects with JWH133 while another CB2 agonist lost efficacy after two days under its repeated-treatment protocol. Shared receptor targeting did not establish equal durability. The compounds were compared in a defined model The experiment used chemically induced osteoarthritis and measured pressure responses and…

Spread the love

Read Article: Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

A 2021 review argued that acute neurocognitive responses to cannabis vary with biological, pharmacological and exposure-related factors. A product label or use-frequency category alone cannot capture all the determinants discussed. The review considered interacting sources of variation It discussed brain-network activity, formulation, use frequency and differences between therapeutic and recreational…

Spread the love

Read Article: An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us